GB2625207A - An antibacterial and procoagulant chest seal and a preparation method thereof - Google Patents
An antibacterial and procoagulant chest seal and a preparation method thereof Download PDFInfo
- Publication number
- GB2625207A GB2625207A GB2317328.9A GB202317328A GB2625207A GB 2625207 A GB2625207 A GB 2625207A GB 202317328 A GB202317328 A GB 202317328A GB 2625207 A GB2625207 A GB 2625207A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibacterial
- procoagulant
- carboxymethyl chitosan
- chest seal
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 29
- 239000003805 procoagulant Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229920001661 Chitosan Polymers 0.000 claims abstract description 41
- 239000010410 layer Substances 0.000 claims abstract description 28
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 24
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 24
- 229920002258 tannic acid Polymers 0.000 claims abstract description 24
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 24
- 229940033123 tannic acid Drugs 0.000 claims abstract description 24
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 24
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000017 hydrogel Substances 0.000 claims abstract description 13
- 239000012945 sealing adhesive Substances 0.000 claims abstract description 12
- 238000004132 cross linking Methods 0.000 claims abstract description 11
- 239000011241 protective layer Substances 0.000 claims abstract description 11
- 239000005038 ethylene vinyl acetate Substances 0.000 claims abstract description 6
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims abstract description 4
- 239000004814 polyurethane Substances 0.000 claims abstract description 4
- 244000043261 Hevea brasiliensis Species 0.000 claims abstract description 3
- 239000004698 Polyethylene Substances 0.000 claims abstract description 3
- 230000003487 anti-permeability effect Effects 0.000 claims abstract description 3
- 229920003052 natural elastomer Polymers 0.000 claims abstract description 3
- 229920001194 natural rubber Polymers 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 18
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 239000003999 initiator Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000006177 biological buffer Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- ZQMHJBXHRFJKOT-UHFFFAOYSA-N methyl 2-[(1-methoxy-2-methyl-1-oxopropan-2-yl)diazenyl]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)N=NC(C)(C)C(=O)OC ZQMHJBXHRFJKOT-UHFFFAOYSA-N 0.000 claims description 2
- 229920003225 polyurethane elastomer Polymers 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 5
- 229920002635 polyurethane Polymers 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 32
- 210000000038 chest Anatomy 0.000 description 29
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 206010052428 Wound Diseases 0.000 description 16
- 230000002439 hemostatic effect Effects 0.000 description 15
- 230000035876 healing Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241000283977 Oryctolagus Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 201000003144 pneumothorax Diseases 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010019027 Haemothorax Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- LBSPZZSGTIBOFG-UHFFFAOYSA-N bis[2-(4,5-dihydro-1h-imidazol-2-yl)propan-2-yl]diazene;dihydrochloride Chemical compound Cl.Cl.N=1CCNC=1C(C)(C)N=NC(C)(C)C1=NCCN1 LBSPZZSGTIBOFG-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 241001515917 Chaetomium globosum Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- 206010035765 Pneumothorax traumatic Diseases 0.000 description 1
- 206010057102 Pyopneumothorax Diseases 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 241001149558 Trichoderma virens Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000005530 hemopneumothorax Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- -1 it can absorb plasma Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L51/00—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
- C08L51/02—Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers grafted on to polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L97/00—Compositions of lignin-containing materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
Abstract
Disclosed is an antibacterial and procoagulant chest seal and method of preparation thereof, the chest seal comprising an outer protective layer, a dressing layer, and a sealing adhesive layer from top to bottom; the dressing layer is obtained by preparing a complex of dialdehyde carboxymethyl chitosan and tannic acid, then grafting the dialdehyde carboxymethyl chitosan in the composite with acrylic acid, and then cross-linking to form a hydrogel. The outer protective layer is preferably a release paper, and the sealing adhesive layer is preferably PE, EVA, PEVA, polyurethane, or a natural rubber with anti-permeability. A method for producing the dialdehyde carboxymethyl chitosan is further disclosed.
Description
DESCRIPTION
An Antibacterial And Procoagulant Chest Seal And A Preparation Method Thereof
Technical Field
[0001] The invention relates to the technical field of medical supplies, in particular to an antibacterial and procoagulant chest seal and a preparation method thereof
Background
[0002] Traumatic pneumothorax is often caused by the puncture of the lung by fractured rib ends, or by bronchial or lung tissue contusion and laceration due to violent acts, or by bronchial or lung rupture caused by a sudden increase in airway pressure. Sharp or firearm injuries that penetrate the chest wall and affect the lungs, bronchi and trachea or esophagus can also cause pneumothorax, and are often hemopneumothorax or pyopneumothorax. In modern warfare, injuries caused by fragments, shrapnel, and other projectiles often occur in the chest and abdomen, resulting in penetrating wounds or deep blind wounds, these injuries can easily lead to open pneumothorax, accompanied by traumatic hemothorax. This poses a serious threat to the life safety of the wounded personnel and is also a significant cause of the reduction of combat personnel.
[0003] In clinical practice, pneumothorax is generally treated by closing chest drainage opening. The existing method ia generally as follow: covering the wound with Vaseline gauze that provides a certain level of sealing, then wrapping with gauze or cotton pad, and finally securing with medical adhesive tape or a thin film patch. However, due to its complex process and the needed materials and devices that are not easily portable, as well as the multiple steps involved, it is difficult to apply in modern warfare. Therefore, portable chest seals have emerged on the market for ease of use.
[0004] Chest seals are convenient to carry and easy to use. By sealing the wound with a chest seal, pneumothorax can be prevented. Chest seals typically use polyurethane composite films, with one side sealed with medical hot melt adhesive. This type of chest seal can quickly close wounds and prevent the formation of pneumothorax. However, in the battlefield, the medical environment is poor and there are a lot of bacteria, and wounds are often accompanied by
DESCRIPTION
heavy bleeding. Failure to stop bleeding in time can cause blood to flow into the chest cavity and form hemothorax, and wound healing is slow, is prone to rupture during the process of the transfer of the wounded, worsening their condition.
[0005] In summary, there is an urgent need for a chest seal that can stop bleeding in time, resist bacterial infection, and promote wound healing in poor medical environments on the battlefield.
Summary of the invention
[0006] Object of the invention: in view of the shortcomings of the prior art, the object of the invention is to provide an antibacterial and procoagulant chest seal and a preparation method thereof to solve the problems of difficulty in stopping bleeding of wounds, susceptibility to bacterial infection and slow wound healing in the prior art.
[0007] Technical scheme: [0008] An antibacterial and procoagulant chest seal comprises an outer protective layer, a dressing layer and a sealing adhesive layer from top to bottom; [0009] the dressing layer is obtained as follows: preparing a complex of dialdehyde carboxymethyl chitosan and tannic acid, then grafting the dialdehyde carboxymethyl chitosan in the composite with acrylic acid, and then cross-linking to form a hydrogel.
[0010] The invention uses carboxymethyl chitosan, utilizing its hydroxyl group to provide grafting sites for further modification, at the same time, as an amphoteric polyelectrolyte, it has good water solubility, film-forming properties and water-absorbing and water retention properties, and can be used as raw material for hydrogel.
[001]] Tannic acid, due to the large number of phenolic hydroxyl groups in its structure, can hinder bacteria from absorbing iron, polysaccharides, amino acids, etc. It can also disrupt bacterial cell walls and membranes, inhibit the formation of biolilms, and thus exhibits strong antibacterial capabilities; at the same time, tannic acid can act as an astringent, stimulating the secretion of basic fibroblast growth factor, and accelerating the healing of internal and external wounds.
[0012] The hydrogel formed by cross-linking in the invention has good biosafety and histocompatibility, and is an excellent hemostatic material. By grafting acrylic acid onto the
DESCRIPTION
hydroxyl sites of dialdehyde carboxymethyl chitosan, and then using a cross-linking agent to form a three-dimensional mesh structure, then a hydrogel dressing layer is formed.
[0013] Further, the outer protective layer is the release paper outer protective layer.
[0014] Further, the sealing adhesive layer is selected from one of PE, EVA, PEVA, polyurethane or natural rubber that has anti-permeability.
[0015] Further, the preparation method of the dialdehyde carboxymethyl chitosan comprises the following steps: [0016] (1) Adding deionized water to the reactor, then adding carboxymethyl chitosan and stirring to dissolve, then adding oxidant and adjusting the system pH to 3.5-4; [0017] (2) Heating the reactor in step (1) to 40-45°C and stirring for 4-5 hours under light-shielding conditions; [0018] (3) Adding ethylene glycol solution to the reactor in step (2), stirring at room temperature for 0.5-1 hour, centrifuging and washing the product, and freeze-drying under vacuum for 20-24 hours to obtain the dialdehyde carboxymethyl chitosan [0019] On the basis of carboxymethyl chitosan, a new active group-aldehyde group is generated through selective oxidation, which can act as part of the cross-linking effect by itself and reduce the use of toxic cross-linking agents.
[0020] Further, the oxidant in step (1) is sodium periodate.
[0021] Further, the tannic acid is pharmaceutical tannic acid. It complies with the national industry standards LY-T 1300, LY-T1640 and LY-T1641. It has high purity and low heavy metal content and can be used in the pharmaceutical field.
[0022] The preparation method of the antibacterial and procoagulant chest seal comprises the following steps: [0023] (1) Adding deionized water to the reactor, then adding dialdehyde carboxymethyl chitosan and stirring to dissolve, then adding biological buffer to adjust the system pH to 88.5, adding tannic acid and mixing evenly, reacting at room temperature for 6-8 hours; [0024] (2) Continuously flowing protective gas into the reactor in step (1), then adding initiator and acrylic acid and stirring evenly, reacting at room temperature for 4-5 hours, then letting it stand for 10-12 hours;
DESCRIPTION
[0025] (3) Adding the cross-linking agent to the reactor in step (2), stirring evenly, sealing, and then letting it stand at room temperature for 10-12 hours to prepare the dressing layer; [0026] (4) Placing the dressing layer in step (3) on top of the sealing adhesive layer, and covering the outer protective layer on the outside of the sealing adhesive layer and dressing layer to prepare the antibacterial and procoagulant chest seal.
[0027] Step (1) Preparing a complex of dialdehyde carboxymethyl chitosan and tannic acid. [0028] Step (2) Grafting acrylic acid on the hydroxyl site of dialdehyde carboxymethyl chitosan, [0029] Step (3) cross-linking to form a hydrogel.
[0030] Further, the mass ratio of the dialdehyde carboxymethyl chitosan, tannic acid and acrylic acid is (1-1.5): (3-5): (10-15).
[0031] Further, the biological buffer in step (1) is selected from one of tris(hydroxyme thyl)aminomethane, N,N-dihydroxyethylglycine or 2-[4-(2-hydroxyethyl)piperazin-1 -yl]eth anesulfoni c acid.
[0032] The buffer selected in the invention is a biological buffer, which has good buffering capacity, has little interference with biochemical processes and has no toxicity to cells.
[0033] Further, the initiator in step (2) is selected from one of 2,2'-azobis[2-(2-imidazo lin-2-yl)propane] dihydrochloride or Dimethyl 2,2'-azobis(2-methylpropionate).
[0034] The initiator selected in the invention is selected from the initiator that does not contain cyano groups. Compared with other initiators, its decomposition products are non-toxic, less harmful to the body, decompose smoothly, and have a high conversion rate. [0035] Further, the cross-linking agent in step (3) is selected from one of 1-Ethy1-3 -0 -dimethylaminopropyl)carbodiim de or N-hydroxysuccinimide.
[0036] The cross-linking agent selected in the invention is non-toxic and has good biocompatibility. Used in combination with dialdehyde carboxymethyl chitosan which has a certain self-cross-linking ability, it has the characteristics of non-toxic and good biocompatibility while ensuring sufficient cross-linking degree.
[0037] Advantageous effects: [0038] 1. The chest seal provided by the invention uses dialdehyde carboxymethyl chitosan.
DESCRIPTION
Chitosan is a natural linear polyaminopolysaccharide linear polymer compound with broad-spectrum antibacterial properties and good biocompatibility, and it has no toxic and side effects on the human body. Hemostasis can be achieved through an electrostatic reaction between the cathode of erythrocyte membrane and the anode of the chitosan surface.
[0039] The invention uses carboxymethyl chitosan, utilizing its hydroxyl group to provide grafting sites for further modification, at the same time, as an amphoteric polyelectrolyte, it has good water solubility, film-forming properties and water-absorbing and water retention properties, and can be used as raw material for hydrogel. On the basis of carboxymethyl chitosan, a new active group-aldehyde group is generated through selective oxidation, which can act as part of the cross-linking effect by itself and reduce the use of toxic cross-linking agents.
[0040] 2. Tannic acid is added to the chest seal provided by the invention. Tannic acid has excellent broad-spectrum antibacterial activity and also has the ability to promote wound healing. Tannic acid, due to the large number of phenolic hydroxyl groups in its structure, can hinder bacteria from absorbing iron, polysaccharides, amino acids, etc. It can also disrupt bacterial cell walls and membranes, inhibit the formation of biofilms, and thus exhibits strong antibacterial capabilities; at the same time, tannic acid can act as an astringent, stimulating the secretion of basic fibroblast growth factor, and accelerating the healing of internal and external wounds.
[0041] 3. The chest seal provided by the invention uses the hydrogel structure. Hydrogel is a substance composed of an infinite three-dimensional network and water. It can be exchanged with body fluids and provide nutrients for the growth of cells and tissues, therefore, it has good biosafety and histocompatibility, and is an excellent hemostatic material. By grafting acrylic acid onto the hydroxyl sites of dialdehyde carboxymethyl chitosan, and then using a cross-linking agent to form a three-dimensional mesh structure, the meshes are interconnected, making it have better water absorption; when in contact with blood, it can absorb plasma, concentrate blood, which can facilitate platelet aggregation, and improve hemostatic effect. [0042] 4. The chest seal provided by the invention is non-toxic and has excellent biocompatibility: the buffer selected in the invention is a biological buffer, which has good
DESCRIPTION
buffering capacity, has little interference with biochemical processes and has no toxicity to cells; the initiator selected in the invention is selected from the initiator that does not contain cyano groups. Compared with other initiators, its decomposition products are non-toxic, less harmful to the body, decompose smoothly, and have a high conversion rate; the cross-linking agent selected in the invention is non-toxic and has good biocompatibility. Used in combination with dialdehyde carboxymethyl chitosan which has a certain self-cross-linking ability, it has the characteristics of non-toxic and good biocompatibility while ensuring sufficient cross-linking degree
Description of Embodiments
[0043] The invention will be described below in combination with specific embodiments. It should be noted that the following embodiments are examples of the invention and are only used to illustrate the invention but not to limit the invention. Other combinations and various improvements within the concept of the invention can be made without departing from the object or scope of the invention.
[0044] The carboxymethyl chitosan used in this invention was purchased from Shandong Fengtai Biotechnology Co., Ltd.; the tannic acid was medicinal tannic acid purchased from Zhangjiajie Jiurui Biotechnology Co., Ltd.; the absorbable hemostatic membrane was Datsing Biopaper purchased from Beijing Datsing Biotechnology Co., Ltd; the chest seal is Pengyue PY191 purchased from Shenyang Pengyue Technology Co., Ltd.; the compact chest seal is NAR HyFin purchased from North American Rescue Company in the United States. The remaining reagents and equipment are conventional reagents and equipment in this technical fi el d.
[0045] The preparation method of the dialdehyde carboxymethyl chitosan: [0046] (I) In parts by weight, adding deionized water to the reactor, then adding 5 parts of carboxymethyl chitosan and stirring to dissolve, then adding 5 parts of sodium periodate and adjusting the system pH to 4; [0047] (2) Heating the reactor in step (1) to 45°C and stirring for 4 hours under light-shielding conditions; [0048] (3) Adding ethylene glycol solution to the reactor in step (2), stirring at room
DESCRIPTION
temperature for 1 hour, centrifuging and washing the product 3 times with tert-butanol, and freeze-drying under vacuum for 24 hours to obtain the dialdehyde carboxymethyl chitosan. [0049] Embodiment 1 [0050] (1) In parts by weight, adding 30 parts of deionized water to the reactor, then adding 1 part of dialdehyde carboxymethyl chitosan and stirring to dissolve, then adding tris(hydroxymethyl)aminomethane solution to adjust the system pH to 8.5, adding 3 parts of tannic acid and mixing evenly, reacting at room temperature for 6 hours, [0051] (2) Continuously flowing nitrogen into the reactor in step (1), then adding 0.05 parts of 2,2'-azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride and 10 parts of acrylic acid and stirring evenly, reacting at room temperature for 4 hours, then letting it stand for 12 hours; [0052] (3) Adding 0.05 parts of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide to the reactor in step (2), stirring evenly, sealing, and then letting it stand at room temperature for 12 hours to prepare the dressing layer, [0053] (4) Placing the dressing layer in step (3) on top of the sealing adhesive layer, and covering the outer protective layer on the outside of the sealing adhesive layer and dressing layer to prepare the antibacterial and procoagulant chest seal.
[0054] Embodiment 2 [0055] Basically the same as Embodiment 1, except that the amount of tannic acid is changed to 5 parts [0056] Embodiment 3 [0057] Basically the same as Embodiment 1, except that the amount of acrylic acid is changed to 15 parts.
[0058] Embodiment 4 [0059] Basically the same as Embodiment 1, except that the amount of dialdehyde carboxymethyl chitosan is changed to 1.5 parts [0060] Comparative Example 1 [0061] Basically the same as Embodiment 1, except that the tannic acid is replaced by an equal amount of sodium hyaluronate.
[0062] Comparative Example 2
DESCRIPTION
[0063] Basically the same as Embodiment 1, except that acrylic acid is replaced by an equal amount of methylenesuccinic acid.
[0064] Comparative Example 3 [0065] Basically the same as Embodiment 1, except that dialdehyde carboxymethyl chitosan is replaced by an equal amount of carboxymethyl chitosan.
[0066] Comparative Example 4 [0067] Absorbable hemostatic membrane.
[0068] Comparative Example 5 [0069] Chest seal.
[0070] Comparative Example 6 [0071] Compact chest seal.
[0072] Performance Testing [0073] 1. Water absorption capacity test: placing 0.5g of the product of Embodiment 1-4 and 0.5g of the product of Comparative Example 1-4 in a 1000m1 beaker respectively, adding 500m1 of distilled water, letting them stand at room temperature for six hours, after the water absorption reaches saturation, filtering out the distilled water, weighing the mass, and calculating the water absorption rate. The results are as follows.
[0074] Sample (m/g) Water Absorption (m/g) Comparative Example (gig) Embodiment 1 0.5 60 120 Embodiment 2 0.5 62 124 Embodiment 3 0.5 59 118 Embodiment 4 0.5 60 120 Comparative Example 1 0.5 46 92 Comparative Example 2 0.5 52 104 Comparative Example 3 0.5 53 106 Comparative Example 4 0.5 50 100 [0075] According to the comparison between Embodiment 1-4 and Comparative Example 4,
DESCRIPTION
it can be seen that the chest seal provided by the invention has stronger water absorption ability, and thus has stronger hemostatic ability. According to the comparison between Embodiment 1-4 and Comparative Example 1-3, it can be seen that tannic acid has excellent water absorption capacity, using acrylic acid to graft, modify and the use of dialdehyde carboxymethyl chitosan can make the prepared hydrogel have better water absorption capacity.
[0076] 2. Hemostatic ability test: Japanese white rabbits were randomly divided into 11 groups. Japanese white rabbits were anesthetized and fixed on the operating table. The femoral vein was surgically exposed and cut transversely. After allowing them to spurt blood freely for 10 seconds, the products of Embodiment 1-4 and Comparative Example 1-6 were used to stop bleeding at the wound. Using gauze to squeeze hemostasis as a blank control, observing the hemostasis time.
[0077] Procoagulant ability test: taking pictures of Japanese white rabbits' wound every 2 days after the injury, and using Image-Pro Plus Version 6.0 image analysis software to calculate Japanese white rabbits' wound areas until the wounds heal.
[0078] Healing rate = (original wound area -unhealed wound area)/original wound areas 100%. The results are as follows.
[0079] Hemostasis time (t/s) Healing rate in 2 days Healing rate in 4 days Healing rate in 6 days Healing rate in 8 days Healing rate in 10 days Blank Control 85 9.7 21.2 29.5 53.1 80.6 Embodiment 1 19 11.2 28.7 49.2 72.9 97.3 Embodiment 2 20 11.5 29.6 50.1 74.2 98.2 Embodiment 3 18 10.4 28.5 48.7 71.1 96.6 Embodiment 4 21 10.1 28.9 49.0 71.5 96.9 Comparative Example 1 32 10.1 21.7 36.2 58.7 86.4 Comparative 28 10.3 25.4 42.9 67.8 90.6
DESCRIPTION
Example 2
Comparative Example 3 30 10.6 26.1 43.1 68.2 91.3 Comparative Example 4 28 11.3 22.9 30.2 55.1 83.3 Comparative Example 5 69 10.8 22.1 29.8 53.4 82.1 Comparative Example 6 65 10.2 21.7 29.2 52.3 81.4 [0080] According to the comparison between Embodiment 1-4, Comparative Example 4-6 and the blank control, in terms of hemostatic ability, the chest seal provided by the invention has hemostatic ability, and has stronger hemostatic ability than conventional hemostatic membranes, hemostasis can be completed in a shorter time; in terms of procoagulant ability, the chest seal provided by the invention basically healed the wound on the 10th day, and is stronger than Japanese white rabbits' own healing ability, achieving the effect of promoting healing; at the same time, it is also stronger than other chest seals and hemostatic products in procoagulant ability. According to the comparison between Embodiment 1-4 and Comparative Example 1-3, it can be seen that tannic acid has better hemostatic ability and procoagulant ability than sodium hyaluronate, using acrylic acid to graft, modify and the use of dialdehyde carboxymethyl chitosan make the prepared hydrogel to have better hemostatic and procoagulant abilities.
[0081] 3. Antibacterial ability test: according to ASTM 21-96 -Standard Practice for Determining Resistance of Synthetic Polymeric Materials to Fungi, the anti-mold performance of the product is tested by using the petri dish method. The samples prepared in Embodiment 1-4 and Comparative Example 1-4 were made into 50m x5Omm specifications and placed flat on the surface of the solidified inorganic salt culture medium. Then preparing a mixed suspension of fungal spores: 5 kinds of molds (Aspergillus niger, Penicillium funiculosum, Chaetomium globosum, Gliocladium virens, and Aureobasidium pullulans), the prepared spore suspension should use spores (1,000,000 ± 200,000) spores/mL, which can be
DESCRIPTION
calculated with a counter. Spraying the spore suspension evenly and finely on the entire surface of the sample, the pressure of the sprayer should reach 110 kPa. After drying slightly, covering the Petri dish lid. Marking the name, number and date of the sample on the cover, placing it in an incubator, and maintaining it at a temperature of 28°C to 30°C and a relative humidity of no less than 85%. The standard cultivation time for the test is 28 days. After 28 days, the evaluation for anti-mold grade is carried out. The results are in the table below. [0082] Anti-mold Grade Embodiment 1 0 Embodiment 2 0 Embodiment 3 0 Embodiment 4 0 Comparative Example 1 2 Comparative Example 2 1 Comparative Example 3 1 Comparative Example 4 3 Comparative Example 5 3 Comparative Example 6 4 [0083] The evaluation criteria for anti-mold grade are as follows: [0084] Anti-mold Grade Evaluation Criteria for Anti-mold Grade 0 No mold growth 1 Trace growth (less than 10%) 2 Slight growth (10-30%) 3 Moderate growth (30-60%) 4 Heavy growth (60%-full coverage) [0085] According to the comparison between Embodiment 1-4 and Comparative Example 46, it can be seen that the chest seal provided by the invention has strong antibacterial ability,
DESCRIPTION
while the chest seals and hemostatic products currently on the market have very poor antibacterial ability. According to the comparison between Embodiment 1-4 and Comparative Examples 1-3, it can be seen that tannic acid has strong antibacterial ability, using acrylic acid to graft, modify and the use of di al dehyde carboxymethyl chitosan can make the prepared hydrogel have better antibacterial ability.
[0086] The above embodiments are only for illustrating the technical concepts and characteristics of the invention. The object is to allow those familiar with this technology to understand the content of the invention and implement it. This does not limit the scope of protection of the invention. MI equivalent changes or modifications made based on the spirit and essence of the invention shall be included in the protection scope of the invention.
Claims (10)
- CLAIMS1. An antibacterial and procoagulant chest seal, wherein it comprises an outer protective layer, a dressing layer and a sealing adhesive layer from top to bottom; the dressing layer is obtained as follows: preparing a complex of dialdehyde carboxymethyl chitosan and tannic acid, then grafting the dialdehyde carboxymethyl chitosan in the composite with acrylic acid, and then cross-linking to form a hydrogel.
- 2. An antibacterial and procoagulant chest seal according to claim 1, wherein the outer protective layer is the release paper outer protective layer.
- 3. An antibacterial and procoagulant chest seal according to claim 1, wherein: the sealing adhesive layer is selected from one of PE, EVA, PEVA, polyurethane or natural rubber that has anti-permeability.
- 4. An antibacterial and procoagulant chest seal according to claim I, wherein: the preparation method of the dialdehyde carboxymethyl chitosan comprises the following steps: (1) Adding deionized water to the reactor, then adding carboxymethyl chitosan and stirring to dissolve, then adding oxidant and adjusting the system pH to 3.5-4; (2) Heating the reactor in step (1) to 40-45°C and stirring for 4-5 hours under light-shielding conditions; (3) Adding ethylene glycol solution to the reactor in step (2), stirring at room temperature for 0.5-1 hour, centrifuging and washing the product, and freeze-drying under vacuum for 20-24 hours to obtain the dialdehyde carboxymethyl chitosan.
- 5. An antibacterial and procoagulant chest seal according to claim 4, wherein the oxidant in step (1) is sodium periodate.
- 6. A preparation method of the antibacterial and procoagulant chest seal according to any one of claims 1-5, wherein: it comprises the following steps: (1) Adding deionized water to the reactor, then adding dialdehyde carboxymethyl chitosan and stirring to dissolve, then adding biological buffer to adjust the system pH to 88.5, adding tannic acid and mixing evenly, reacting at room temperature for 6-8 hours; (2) Continuously flowing protective gas into the reactor in step (1), then adding initiator and acrylic acid and stirring evenly, reacting at room temperature for 4-5 hours, then letting it stand for 10-12 hours; (3) Adding the cross-linking agent to the reactor in step (2), stirring evenly, sealing, andCLAIMSthen letting it stand at room temperature for 10-12 hours to prepare the dressing layer; (4) Placing the dressing layer in step (3) on top of the sealing adhesive layer, and covering the outer protective layer on the outside of the sealing adhesive layer and dressing layer to prepare the antibacterial and procoagulant chest seal.
- 7. A preparation method of the antibacterial and procoagulant chest seal according to claim 6, wherein: the mass ratio of the dialdehyde carboxymethyl chitosan, tannic acid and acrylic acid is (1-1.5): (3-5): (10-15).
- 8. A preparation method of the antibacterial and procoagulant chest seal accordin g to claim 6, wherein: the biological buffer in step (1) is selected from one of tris(hy droxymethyDaminomethane, N,N-dihydroxyethylglycine or 2-[4-(2-hydroxyethyl)piperazin - I -yl]eth an esul foni c acid.
- 9. A preparation method of the antibacterial and procoagulant chest seal accordin g to claim 6, wherein: the initiator in step (2) is selected from one of 2,2'-azobis[2-(2 -imidazolin-2-yepropane] dihydrochloride or Dimethyl 2,2'-azobis(2-methy-lpropionate).
- 10. A preparation method of the antibacterial and procoagulant chest seal according to claim 6, wherein: the cross-linking agent in step (3) is selected from one of 1-Ethy1-3 -(3 -dimethyl aminopropyl)carbodiimi de or N-hydroxysuccinimide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211434594.8A CN115869452A (en) | 2022-11-16 | 2022-11-16 | Antibacterial procoagulant pneumothorax sealing patch and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202317328D0 GB202317328D0 (en) | 2023-12-27 |
| GB2625207A true GB2625207A (en) | 2024-06-12 |
Family
ID=85760020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2317328.9A Pending GB2625207A (en) | 2022-11-16 | 2023-11-13 | An antibacterial and procoagulant chest seal and a preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115869452A (en) |
| GB (1) | GB2625207A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101547A1 (en) * | 2002-11-26 | 2004-05-27 | Pendharkar Sanyog Manohar | Wound dressing containing aldehyde-modified regenerated polysaccharide |
| CN113941025A (en) * | 2021-10-27 | 2022-01-18 | 四川大学华西医院 | Tissue-adhesive hydrogel and application thereof |
| CN114230812A (en) * | 2021-12-07 | 2022-03-25 | 广东省科学院健康医学研究所 | Functional hydrogel and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103709267A (en) * | 2013-11-28 | 2014-04-09 | 江南大学 | Preparation method of dialdehyde carboxymethyl chitosan |
| CN213156978U (en) * | 2020-06-30 | 2021-05-11 | 泰州市榕兴医疗用品股份有限公司 | Thoracic cavity sealing patch |
| CN113069166A (en) * | 2021-03-01 | 2021-07-06 | 河南神龙战救医疗装备有限公司 | Chest sealing patch with hemostasis function |
| CN114832153A (en) * | 2022-05-06 | 2022-08-02 | 奥美医疗用品股份有限公司 | Polysaccharide fabric reinforcing base antibacterial hemostatic multifunctional hydrogel dressing |
-
2022
- 2022-11-16 CN CN202211434594.8A patent/CN115869452A/en active Pending
-
2023
- 2023-11-13 GB GB2317328.9A patent/GB2625207A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101547A1 (en) * | 2002-11-26 | 2004-05-27 | Pendharkar Sanyog Manohar | Wound dressing containing aldehyde-modified regenerated polysaccharide |
| CN113941025A (en) * | 2021-10-27 | 2022-01-18 | 四川大学华西医院 | Tissue-adhesive hydrogel and application thereof |
| CN114230812A (en) * | 2021-12-07 | 2022-03-25 | 广东省科学院健康医学研究所 | Functional hydrogel and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Polymer Materials, 34, Long, Zhu et al., 2017, "Synthesis & characterization of dialdehyde carboxymethyl chitosan", 207-221 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115869452A (en) | 2023-03-31 |
| GB202317328D0 (en) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Double crosslinking chitosan sponge with antibacterial and hemostatic properties for accelerating wound repair | |
| EP1123104B1 (en) | Inherently antimicrobial quaternary amine hydrogel wound dressings | |
| US20120316129A1 (en) | Liquid dressing containing chitosan derivative and preparation method thereof | |
| CN112300420B (en) | Injectable antibacterial interpenetrating double-network hydrogel and preparation method and application thereof | |
| CN111690078B (en) | Double-quaternized chitosan derivative, synthetic method thereof, composite sponge biological dressing containing double quaternized chitosan derivative and application of composite sponge biological dressing | |
| CN107854716B (en) | Antibacterial and dehumidifying dressing patch and preparation method thereof | |
| EP4019056A1 (en) | Method to produce in situ self-assembled multifunctional nanocomposite hydrogel and its uses thereof | |
| US11938230B2 (en) | Hemostatic material and wound dressing containing same | |
| CN103848926A (en) | Preparation method and applications of carboxylation chitosan | |
| CN104491918A (en) | Novel antibacterial hydrocolloid dressing and preparation method thereof | |
| CN113069591A (en) | Chitosan-calcium polyglutamate biological dressing and preparation method thereof | |
| CN112121238A (en) | Multifunctional composite anti-adhesion material and preparation method thereof | |
| CN106139239A (en) | Full-service fluid dressing and preparation method thereof | |
| CN109498834B (en) | Antibacterial hydrocolloid dressing and preparation method thereof | |
| RU2519220C1 (en) | Local hemostatic agent | |
| CN109364286B (en) | Graphene oxide composite nanofiber structure dressing and preparation method thereof | |
| Wang et al. | Composite hydrogel based oxidated sodium carboxymethyl cellulose and gelatin loaded carboxymethylated cotton fabric for hemostasis and infected wound treatment | |
| CN108815562A (en) | A kind of preparation method of compound hemostatic material | |
| GB2625207A (en) | An antibacterial and procoagulant chest seal and a preparation method thereof | |
| CN113209361B (en) | Biological material composite hydrogel wound dressing and preparation method thereof | |
| CN111184906A (en) | PVA-based liquid dressing and preparation method thereof | |
| CN107185026B (en) | Preparation method of medical konjac glucomannan antibacterial dressing | |
| CN109701070A (en) | A kind of antibacterial hybridized nanometer flower hemostatic material and preparation method thereof | |
| Sang et al. | Wool keratin/zeolitic imidazolate framework-8 composite shape memory sponge with synergistic hemostatic performance for rapid hemorrhage control | |
| CN112472867A (en) | Antibacterial medical hydrogel dressing and preparation method thereof |